Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. / Bjørn, Mads Emil; Andersen, Christen Lykkegaard; Jensen, Morten Krogh; Hasselbalch, Hans C.
I: European Journal of Haematology, Bind 93, Nr. 3, 2014, s. 224-228.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state
AU - Bjørn, Mads Emil
AU - Andersen, Christen Lykkegaard
AU - Jensen, Morten Krogh
AU - Hasselbalch, Hans C.
PY - 2014
Y1 - 2014
N2 - Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL-40 as a biomarker of disease burden has been demonstrated in several different diseases, including cancer, diabetes mellitus and cardiovascular diseases. A state of chronic inflammation is shared by them all, YKL-40 also being involved in the severity of chronic endothelial inflammation, which today is considered of crucial importance for the development of atherosclerosis. The MPNs being cancers with a heavy burden of cardiovascular diseases we hypothesised that circulating YKL-40 might reflect the inflammatory process and potentially serve as a novel disease marker. Using ELISA, we measured YKL-40 in 15 patients with ET, 16 patients with PV, 17 patients with PMF and 30 healthy controls. YKL-40 was significantly elevated in PMF vs. control subjects, PMF levels median 43 ng/mL vs. controls median 28 ng/mL, P = 0.033. An increase from ET over PV may reflect the integrated impact of disease processes in MPNs.
AB - Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL-40 as a biomarker of disease burden has been demonstrated in several different diseases, including cancer, diabetes mellitus and cardiovascular diseases. A state of chronic inflammation is shared by them all, YKL-40 also being involved in the severity of chronic endothelial inflammation, which today is considered of crucial importance for the development of atherosclerosis. The MPNs being cancers with a heavy burden of cardiovascular diseases we hypothesised that circulating YKL-40 might reflect the inflammatory process and potentially serve as a novel disease marker. Using ELISA, we measured YKL-40 in 15 patients with ET, 16 patients with PV, 17 patients with PMF and 30 healthy controls. YKL-40 was significantly elevated in PMF vs. control subjects, PMF levels median 43 ng/mL vs. controls median 28 ng/mL, P = 0.033. An increase from ET over PV may reflect the integrated impact of disease processes in MPNs.
KW - chronic inflammation
KW - YKL-40
KW - JAK2V617F
KW - myeloproliferative neoplasia (MPN)
KW - biomarker
KW - cytokines
KW - CHRONIC MYELOPROLIFERATIVE DISORDERS
KW - COLONIC EPITHELIAL-CELLS
KW - LEUKEMIA-FREE SURVIVAL
KW - JAK2 V617F MUTATION
KW - C-REACTIVE PROTEIN
KW - POLYCYTHEMIA-VERA
KW - ESSENTIAL THROMBOCYTHEMIA
KW - SERUM YKL-40
KW - ENDOTHELIAL DYSFUNCTION
KW - PLASMA YKL-40
U2 - 10.1111/ejh.12332
DO - 10.1111/ejh.12332
M3 - Journal article
VL - 93
SP - 224
EP - 228
JO - Scandinavian Journal of Haematology
JF - Scandinavian Journal of Haematology
SN - 0902-4441
IS - 3
ER -
ID: 332927627